MedTrace Logo

A Retrospective Review Evaluating the Matrix Pro Applicator for Treatment of Wrinkles

NCT06219278 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 32

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

This is a retrospective chart review of data from the multi-site prospective clinical trial, "Functional Usability and Feasibility Testing of the Profound Matrix™ System (FUFT2002)" to evaluate the safety and efficacy of the Profound Matrix System Matrix Pro applicator for the treatment of wrinkles.

Conditions

  • Wrinkle

Interventions

DEVICE

Profound Matrix

The source study consisted of up to three treatment visits with treatment intervals 6 weeks ± 2 weeks

Sponsors & Collaborators

  • Candela Corporation

    lead INDUSTRY

Principal Investigators

  • Konika Patel Schallen, MD · Candela Medical

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-29
Primary Completion
2023-12-29
Completion
2024-07-01
FDA Device
Yes

Countries

  • United States
  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06219278 on ClinicalTrials.gov